Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grifols' US arm to sell ADI's colon cancer monitor

This article was originally published in Clinica

Executive Summary

AMDL Diagnostics (ADI) has enlisted Grifols, one of Spain's largest and most established healthcare multinationals, as the exclusive distributor of its colorectal cancer test. The five-year agreement will see Grifols USA market the DR-70 Onko-Sure test to hospitals and labs nationwide, for monitoring the recurrence of colorectal cancer. ADI was created in August by its parent company, Tustin, California-based Radient Pharmaceuticals (formerly known as AMDL), to focus exclusively on the commercialisation of Onko-Sure (www.clinica.co.uk, August 21 2009). According to Radient, around 151,000 new cases of colorectal cancer were diagnosed in the US in 2008 – almost half of all patients thought to be cured are expected to develop a recurrence of the cancer within five years, usually due to undetected metastases.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel